Teneligliptin
Teneligliptin has been studied in 7 papers since 2018: 2 trials and 2 observational studies in people, 2 in animals, 1 review; 2 in the past year. The newest paper, Nov 14, 2026: “Efficacy and safety of teneligliptin as add‐on therapy in patients with type 2 diabetes treated with empagliflozin and metformin: A 24‐week, randomized, double‐blind, placebo‐controlled phase 3 trial”.
7 papers study it8 findingsUpdated
1 new paper in 30 daysSee all 7 papers on teneligliptin
At a glance
Independent labs found the same change in people. 3 independent labs in 2 countries; 21 trials, 8 about aging, 10 with no results posted.
“At week 24, the teneligliptin group showed a significant reduction in HbA1c compared with the placebo group”
None of its findings points the other way.
- 3 independent labs in 2 countries
- 21 trials, 8 about aging, 10 with no results posted
- Funder: Handok
- 6 of 7 findings with company ties
- 21 of 21 trials sponsored by its developers
- Human trial2
- Humans2
- Animals2
Studies in people
2 studies gave teneligliptin to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases HbA1cLeast-squares mean difference −0.69 percentage points; 95% CI −0.83 to −0.54 no change: Has no effect on treatment-emergent adverse events | Randomized trial24 weeks | 119 peopleKorean patients with type 2 diabetes inadequately controlled with empagliflozin and metformin | Journal of diabetes investigation, Nov 14, 2026 |
down: Decreases HbA1c-0.76% (95% CI, -1.08 to -0.44) up: Increases TIR70-18013.3% (95% CI, 6.0 to 20.6) down: Decreases glycemic variability | Randomized trial12 weeks | 65 people≥65 yearsOlder adults; elderly type 2 diabetes mellitus | Diabetes & metabolism journal, Jun 16, 2021 |
What did studies of teneligliptin find?
7Studies of teneligliptin measured 7 outcomes, among them HbA1c, treatment-emergent adverse events and type 2 diabetes.
HbA1c
downin humans2
2 studies
HbA1c
downin humans2
Teneligliptin decreases HbA1c in humans (Least-squares mean difference −0.69 percentage points; 95% CI −0.83 to −0.54).
Human trialKorean patients with type 2 diabetes inadequately controlled with empagliflozin and metformin; compared with placebo20 mg once daily24 weeks
Teneligliptin decreases HbA1c in humans (elderly type 2 diabetes mellitus) (-0.76% (95% CI, -1.08 to -0.44)).
Human trialelderly type 2 diabetes mellitus20 mg12 weeksn = 65
Treatment-emergent adverse events
no changein humans1
1 study
Treatment-emergent adverse events
no changein humans1
Teneligliptin showed no clear effect on treatment-emergent adverse events in humans.
Human trialKorean patients with type 2 diabetes receiving empagliflozin and metformin; compared with placebo20 mg once daily24 weeks
Type 2 diabetes
downin humans1
1 study
Type 2 diabetes
downin humans1
Teneligliptin decreases type 2 diabetes in humans.
Review
Hypoglycemia
no changein humans1
1 study
Hypoglycemia
no changein humans1
Teneligliptin showed no clear effect on hypoglycemia in humans (elderly type 2 diabetes mellitus).
Human trialelderly type 2 diabetes mellitus20 mg12 weeksn = 65
Glycemic variability
downin humans1
1 study
Glycemic variability
downin humans1
Teneligliptin decreases glycemic variability in humans (elderly type 2 diabetes mellitus).
Human trialelderly type 2 diabetes mellitus20 mg12 weeksn = 65
TIR70-180
upin humans1
1 study
TIR70-180
upin humans1
Teneligliptin increases TIR70-180 in humans (elderly type 2 diabetes mellitus) (13.3% (95% CI, 6.0 to 20.6)).
Human trialelderly type 2 diabetes mellitus20 mg12 weeksn = 65
Skeletal muscle mass
no changein humans1
1 study
Skeletal muscle mass
no changein humans1
Teneligliptin showed no clear effect on skeletal muscle mass in T2DM patients on hemodialysis (18.6 kg to 18.9 kg, P = 0.16).
Human trialin T2DM patients on hemodialysissix monthsn = 10
Has teneligliptin been tested in people?
8 of 21 about agingYes: 2 trials and 2 observational studies in people have been published.
About aging
Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 Diabetes
Phase 3Completed
Phase 3Completed
Phase 3Completed
Phase 3Completed
Tenelia Elderly CGMS Study(TEDDY)
Phase 4Completed
Phase 3Completed
All 8Fewer
Who is developing teneligliptin?
2 companies: Tanabe Pharma and Handok.
Trial sponsors
Company10 trialsPhase 4694 people
Company8 trialsPhase 41,478 people